The Neuroprotective Effect of PEG-GCSF in the Traumatic Optic Neuropathy

Last updated: December 4, 2023
Sponsor: Buddhist Tzu Chi General Hospital
Overall Status: Active - Recruiting

Phase

1

Condition

N/A

Treatment

Neulasta® (pegfilgrastim)

Clinical Study ID

NCT06168188
TCMF-EP 108-01
  • Ages 20-70
  • All Genders

Study Summary

The clinical trial will be a phase 1, semi-experimental trial, which will be performed in Hualien Tzu Chi Hospital. Twenty patients will be recruited in this study starting from the 2nd year of the project to the 3rd year of the project and will go through comprehensive eye and systemic examination in the Hualien Tzu Chi Hospital. Indirect TON (ITON) patients are defined as reduced best corrected visual acuity (BCVA), visual field, color vision, and positive relatively afferent pupillary defect (RAPD) with normal fundus and optic nerve examination and no evidence of direct trauma to optic nerve on spiral orbital and optic canal computer tomography (CT) scan. Therefore, all patients will have examinations of BCVA, visual field, color vision, RAPD, FVEP, CT scan, and IOP for defining ITON patients one day before Neulasta injection. Patient also underwent renal function test, liver function test, coagulation test, and complete blood count before the treatment. Patients who meet the enrollment criteria (inclusion and exclusion) will be fully informed of this treatment and then an informed consent will be obtained. After patient enrolment, the patient will be intravitreally administrated by 0.15 mL of Neulasta in the injured eye. Firstly, the injured eye will be treated with iodine solution for disinfection and then will be treated with Alcaine eye drop for topic anesthesia. The 0.15 mL of Neulasta will be filled into 1 mL of syringe equipped with 30 gauge beveled needle for intravitreal injection. During injection of Neulasta solution, the anterior chamber decompression will be performed for IOP balance. The aqueous humor from anterior chamber will be collected for further microarray analysis. After Neulasta treatment, Tobradex eyedrops (Alcon) will be given on the injected eye, four times a day. Patient will be hospitalized for one day to monitor BCVA, IOP, fundus condition, complete blood count, and any adverse event. During 3-month follow-up trial, each patient will be regularly monitored 7 days and 1, 3 months after treatments by determining the BCVA, the RPAD, the color vision, visual field, the latency of P-100 wave in FVEP, and the RNFL thickness, IOP, and complete blood count.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. 20-70 years old
  2. Having indirect traumatic optic neuropathy, one week to 4 weeks after trauma
  3. Normal disc figure and macula appearance
  4. Reduced BCVA (Snellen Chart, less than 20/200) or C-24 central visual field loss morethan 10 dB (MD<-10 dB)
  5. Color vision defect and positive RAPD
  6. No evidence of direct trauma to ON on spiral orbital and optic canal computertomography (CT) scan.
  7. Normal IOP (10-21 mm Hg)
  8. Normal blood coagulation (prothrombin time: 812s; partial thromboplastin time: 23.9 - 35.5 s; international normalized ratio: 0.851.15)
  9. Adequate hematologic (absolute neutrophil count ≥1.5 × 109/L, hemoglobin ≥9 g/dL,platelets ≥80 × 109/L, and PT/PTT/INR ≤1.0 × upper limit of normal; ULN)
  10. Adequate hepatic function (albumin ≥2.8 g/dL, serum bilirubin ≤2.0 mg/dL or ≤2 × ULN,and aspartate aminotransferase and alanine aminotransferase ≤5.0 × ULN)
  11. Adequate renal function (Serum BUN: 6-22 mg/dl; serum creatinine: 0.7-1.5 mg/dl formen, 0.5-1.2 mg/dl for women)
  12. No other cranial nerve injuries (cranial nerve examination, nerve number: 1, 3-12)

Exclusion

Exclusion Criteria:

  1. Having other injuries that effect on visual function
  2. Direct optic neuropathy
  3. No light perception
  4. Pregnant and breast feeding women
  5. Having malignancy
  6. Sickle-cell disease
  7. G-CSF allergic reaction
  8. Acute infectious diseases
  9. Benign Intracranial hypertension symptoms (1. papilledema in both eyes with nospontaneous venous pulsation 2. Increase of peripapillary nerve fiber layer thicknessin OCT imaging)
  10. Associated intracranial hemorrhage or severe skull fracture
  11. History or evidence of any other clinically condition that, in the opinion of theinvestigator, would pose a risk to patient's safety or interfere with studyprocedures, evaluation, or completion:
  12. Diabetic retinopathy, maculopathy
  13. Uncontrolled hypertension
  14. History of stroke and cardiovascular diseases
  15. Glaucoma

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Neulasta® (pegfilgrastim)
Phase: 1
Study Start date:
July 24, 2020
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

    Taipei, Not US Or Canada 970
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.